7,430.25

+28.25

+0.38%

51,750.00

+365.00

+0.71%

27,085.50

+0.25

+0.00%

Russell 2000 Futures

2,787.70

+27.20

+0.99%

4.8590

+0.0220

+0.45%

24.07

-1.57

-6.12%

4,103.90

+29.00

+0.71%

74,546.77

-1,271.91

-1.68%

Crude Oil Dec 26

89.80

-1.03

-1.13%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Nasdaq Real Time Price USD

Femasys Inc. (FEMY)

1.3700 +0.0600 (+4.58%)

At close: November 6 at 4:00:01 PM EST

Loading Chart for FEMY

Chart Range Bar

Interval:

In partnership with ChartIQ

Femasys Appoints John Moorhead to Board of Directors

Femasys Appoints John Moorhead to Board of Directors

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands

Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential

FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential

Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc

Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

Mobilize your Website

View Site in Mobile | Classic

Share by: